Epigenetic Control of the Immune Escape Mechanisms in Malignant Carcinomas

ABSTRACT Downregulation of the transporter associated with antigen processing 1 (TAP-1) has been observed in many tumors and is closely associated with tumor immunoevasion mechanisms, growth, and metastatic ability. The molecular mechanisms underlying the relatively low level of transcription of the tap-1 gene in cancer cells are largely unexplained. In this study, we tested the hypothesis that epigenetic regulation plays a fundamental role in controlling tumor antigen processing and immune escape mechanisms. We found that the lack of TAP-1 transcription in TAP-deficient cells correlated with low levels of recruitment of the histone acetyltransferase, CBP, to the TAP-1 promoter. This results in lower levels of histone H3 acetylation at the TAP-1 promoter, leading to a decrease in accessibility of the RNA polymerase II complex to the TAP-1 promoter. These observations suggest that CBP-mediated histone H3 acetylation normally relaxes the chromatin structure around the TAP-1 promoter region, allowing transcription. In addition, we found a hitherto-unknown mechanism wherein interferon gamma up-regulates TAP-1 expression by increasing histone H3 acetylation at the TAP-1 promoter locus. These findings lie at the heart of understanding immune escape mechanisms in tumors and suggest that the reversal of epigenetic codes may provide novel immunotherapeutic paradigms for intervention in cancer.

[1]  M. Matsui,et al.  Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon‐γ , 2002, Journal of gastroenterology and hepatology.

[2]  P. Riddle,et al.  Metastasizing tumors from serum-supplemented and serum-free cell lines from a C57BL mouse lung tumor. , 1976, Cancer research.

[3]  D. Templeton,et al.  Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. , 1999, Journal of immunology.

[4]  P. Gregory,et al.  Histone acetylation and chromatin remodeling. , 2001, Experimental cell research.

[5]  K. Struhl.  Histone acetylation and transcriptional regulatory mechanisms. , 1998, Genes & development.

[6]  T. Timme,et al.  Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells. , 2000, Cancer research.

[7]  Victor V Lobanenkov,et al.  The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. , 2002, Seminars in cancer biology.

[8]  S. Berger,et al.  Histone modifications in transcriptional regulation. , 2002, Current opinion in genetics & development.

[9]  E. Kalkhoven,et al.  CBP and p300: HATs for different occasions. , 2004, Biochemical pharmacology.

[10]  J. Herman,et al.  Epigenetic regulation of protein phosphatase 2A (PP2A), Lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells , 2004, Cancer biology & therapy.

[11]  B. Seliger,et al.  Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin. , 2000, Tissue antigens.

[12]  V. Vonka,et al.  Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. , 2003, Vaccine.

[13]  U. Ritz,et al.  The Transporter Associated With Antigen Processing (TAP): Structural Integrity, Expression, Function, and Its Clinical Relevance , 2001, Molecular medicine.

[14]  Antonio Giordano,et al.  p300 and CBP: Partners for life and death , 1999, Journal of cellular physiology.

[15]  W. Jefferies,et al.  Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing , 1994, The Journal of experimental medicine.

[16]  I. Fidler,et al.  In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties. , 1980, Cancer research.

[17]  L. Mahadevan,et al.  Phosphorylation and acetylation of histone H3 at inducible genes: two controversies revisited. , 2004, Novartis Foundation symposium.

[18]  P. Becker,et al.  Histone acetylation: a switch between repressive and permissive chromatin , 2002, EMBO reports.

[19]  P. Becker,et al.  Dynamic chromatin: concerted nucleosome remodelling and acetylation , 2005, Biological chemistry.

[20]  D. Hicklin,et al.  Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. , 1999, The American journal of pathology.

[21]  B. Seliger,et al.  Antigen-processing machinery breakdown and tumor growth. , 2000, Immunology today.

[22]  W. Jefferies,et al.  Identification of mechanisms underlying transporter associated with antigen processing deficiency in metastatic murine carcinomas. , 2005, Cancer research.

[23]  B. Seliger,et al.  TAP off--tumors on. , 1997, Immunology today.

[24]  Robert Tampé,et al.  The transporter associated with antigen processing: function and implications in human diseases. , 2002, Physiological reviews.

[25]  H. Gascan,et al.  Functional Interaction of STAT3 Transcription Factor with the Coactivator NcoA/SRC1a* , 2002, The Journal of Biological Chemistry.

[26]  D. Trouche,et al.  Regulating histone acetyltransferases and deacetylases , 2003, EMBO reports.

[27]  Wilfred A. Jefferies,et al.  TAP expression provides a general method for improving the recognition of malignant cells in vivo , 2000, Nature Biotechnology.

[28]  J. Davie,et al.  Control of histone modifications , 1999, Journal of cellular biochemistry.

[29]  F. Guarnieri,et al.  Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. , 1996, Cancer research.